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Summary 
The cleavage of C3 is a critical step for complement (C) activation in the classical and alternative 
pathways. This reaction is controUed by the regulators of C activation protein family. Membrane 
cofactor protein (MCP) is a cofactor for the factor I-mediated inactivation of C3b and C4b. 
As a widely distributed membrane protein, MCP may protect host cells from inadvertent C 
activation. Human MCP has recently been shown to protect transfected rodent cells from human 
C-mediated lysis. In this report the relationship of MCP expression  to C3b deposition and 
cytoprotection was examined using NIH/3T3 cells transfected with human MCP and exposed 
to human serum as a source of C and naturally occurring anti-mouse antibody. MCP inhibited 
C3b deposition in a dose-dependent fashion and inhibited lysis of the mouse cells expressing 
it. MCP did not inhibit lysis on bystander cells. These results demonstrate the protective role 
of MCP, at the cellular level, by an intrinsic mechanism. 
T 
he human C system is an independent immune system 
that can separate self from nonself and function as a po- 
tent effector system (1). C components are spontaneously and 
continuously deposited on self tissue in small amounts (2), 
and in larger quantities during inflammatory reactions. Mem- 
brane cofactor protein (MCP; 1 CD46) and decay-accderating 
factor (DAF; CD55) are membrane glycoproteins that pro- 
tect host cells from damage by the C  system (reviewed in 
references 3 and 4). MCP is a cofactor for the factor I-medi- 
ated cleavage of C3b and C4b, while DAF accelerates decay 
dissociation of the C3 and C5 convertases. Both proteins are 
widely distributed on hematopoietic, endothelial, and epi- 
thdial cells. They are also highly expressed on certain malig- 
nant cell lines  (3-7)  and reproductive tissues  (8). 
DAF is a glycolipid-anchored protein and functions intrin- 
sically; that is, it protects only the cell on which it is ex- 
pressed (9). The same mechanism has been postulated for MCP 
(3, 10, 11). Although experiments to date are consistent with 
this interpretation (11-15), the question has not been directly 
tested. 
Oglesby et al. (14), Atkinson et al. (15), and Lublin and 
Abbreviations used in this paper: DAF, decay-accderating factor;  MCP, 
membrane cofactor protein; NHS, normal human serum. 
Coyne (13) have used nonhuman cell lines transfected with 
the human MCP or DAF gene to demonstrate the capacity 
of these proteins to protect cells from C-mediated damage. 
Seya et al. (12) have also shown that human T cell lines ex- 
pressing MCP but no other C regulatory protein became sus- 
ceptible to lysis by the alternative pathway if the activity of 
MCP was blocked by a mAb. 
To further assess the mechanism of the inhibitory effect 
of MCP on C activation, mouse fibroblasts were transfected 
with human MCP and then exposed to human serum. Only 
those cells on which MCP was expressed were protected from 
lysis by human C. This intrinsic mechanism of cytoprotec- 
tion by MCP and the quantitative aspects of its activity could 
be of interest to tumor, transplant, and reproductive immu- 
nologists. 
Materials and Methods 
Transfectant Cell Lines.  NIH/3T3 cells (raouse  fibroblast; Amer- 
ican Type Cell Culture, Rockville, MD) were stably transfected 
with forward or reverse oriented fuU-length cDNA of an upper 
band isoform of MCP (16, 17). The cDNA was inserted into the 
EcoRI site of the pHBAPr-l-neo vector (18) and transfected into 
cells using Lipofectin  |  reagent (Bethesda Research Laboratories, 
Gaithersburg, MD). Transfected  cells were selected for neomycin 
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serum and Geneticin  |  (0.4 mg/ml; Gibco  BILL,  Gaithersburg, MD). 
MCP expression was confirmed by immunoprecipitation of 
3SS-cysteine~labeled  cell lysates with the anti-MCP mAb E4.3 (3, 
6, 19), followed by SDS-PAGE on 10% mini-slab gels and autora- 
diography (6). An ELISA (20) and FACS  |  (Becton Dickinson & 
Co., Mountain View, CA) analysis  of the transfectants and control 
ceils (MCP-positive and -negative ceil lines) allowed quantitation 
of surface MCP. Cells with low to avenge (<50,000 molecules/cell) 
or high (~500,000) expression were chosen for further use. A low 
expressing line of 25,000 copies (MCP 1-3T3) was sorted three 
times by flow cytometry to obtain cells  with intermediate (180,000) 
MCP expression (MCP 2-3T3). In addition, an unsorted transfec- 
rant with high (~106) MCP expression was also used (MCP 3- 
3T3). Nontransfected  ceils  or transfectants  with the MCP construct 
in reverse  orientation (reverse or R-3T3) served  as controls and were 
interchangeable. 
Quantitation of MCP.  MCP in I% NP-40 lysates of the trans- 
fectants was quantitated by a dual mAb ELISA  (20) in which GB24 
(6, 20, 21) was the capture Ab and TRA-2-10 (6, 22) was the de- 
tection Ab. MCP on the ceil surface  was also quantitated by radio- 
assay using a single radiolabeled mAb (6). Standards for quantita- 
tion by ELISA,  radioassay,  and FACS  |  included  the HeLa and HEp-2 
cell lines, obtained  from the Tissue Culture Support  Center, 
Washington University School of Medicine. 
Detection of C3 Fragment Deposition by FACS  @.  C6-deficient 
(C6D) normal human serum (Quidel, San Diego, CA) was diluted 
1/6 in veronal-buffered  saline containing 0.15 mM CaClz, I mM 
MgClz,  2.5%  dextrose,  0.1%  gelatin,  and  75  mM  NaC1 
(DGVB  z§  (final dilution,  1:9), and 600/~1 was incubated with 
300/~l of MCP-transfected ceils (l(P/ml in DGVB  2+) at 37~  for 
I h. The ceils were washed and C3 fragment deposition was deter- 
mined by FACS  |  analysis using an anti-C3c mAb  (Quidel) or 
MOPC 21 (Sigma Chemical Co., St. Louis, MO) followed by an 
FITC goat anti-mouse IgG (Cappel Laboratories, Durham, NC). 
Cytotoxicity  Assays.  Cytotoxicity  was assessed  by SlCr release. 
Transfectant and control cells were labeled with SlCr (100/~Ci/106 
cells) at room temperature for 1.5 h. 
Normal human serum (NHS) contains naturally occurring anti- 
mouse Ab and C. In some experiments, NHS diluted in DGVB  2  § 
served as a source of C and naturally occurring anti-mouse Ab. 
In other experiments, the NHS was absorbed twice at 4~  with 
mouse spleen cells and used as a C source. In these experiments 
the source of Ab was heat-inactivated (56~  for 30 min) NHS. 
In duplicate or triplicate, 50 ~! (106/ml) of S~Cr-hbeled ceils was 
next incubated with 100/~1 NHS  (1:5 to 1:20 in DGVB  2§  at 
37~  for 1 h. Calls were then pelleted by centrifugation, and 100 
/~1 of supernatant was counted on a gamma counter (4000; Beckman 
Instruments, Inc., Palo Alto, CA). Percent specific  SlCr release was 
calculated by the formula: (cpm -  cpm buffer only [spontaneous 
release]/(cpm 100% lysis -  cpm buffer only). In each experiment, 
the percent lysis  of the MCP transfectants was compared with that 
of a nontransfected control, or the R-3T3 transfectant. Specificity 
of the cytoprotection  was determined  by addition of the mAb GB24 
at a final concentration of 10/~g/ml. 
The ability of human MCP to protect transfected murine ceils 
by an intrinsic versus an extrinsic mechanism was assessed  by per- 
forming the cytotoxicity assay above with the following modi- 
fication: 50 ~1 of unhbeled ceUs (MCP 3-3T3 transfectant or con- 
trol at 106 cells/m1) was added to 50/~1 of slCr-labeled cells (MCP 
3-3T3 transfectant or control at 10  ~ cells/m1), and then the mix- 
ture was incubated with NHS. 
For cytotoxicity assays, each condition was performed in dupli- 
cate or triplicate and each experiment was performed three or four 
times. 
Results 
Quantitation of  MCP on Tmnsflcted  Celk  Three MCP trans- 
fectants, expressing  2.5  x  10  ~ copies of MCP/ceU (MCP 1); 
1.8  x  lOVceU (MCP 2), and 106/ceil (MCP 3), were chosen 
for study. MCP 1, MCP 2, and MCP 3 express a copy number 
of MCP similar to PBL, HeLa, and HEp-2, respectively (6). 
Periodic FACS  |  ELISA, and radioassay analyses of MCP ex- 
pression were internally consistent and did not change during 
this investigation. 
Protection of Murine Cells  from Human C-mediated Lysis by 
Expression of Human MCP.  Three transfectants, expressing 
low, intermediate, or high amounts of MCP, were exposed 
to NHS (the C and Ab source) (Fig. 1 a). A protective effect 
was observed over a fourfold range of serum dilution but was 
less pronounced at the higher serum concentrations. There 
was also a trend toward more lysis (less protection) in the 
low-expressing MCP 1 than in the MCP 2 or MCP 3 trans- 
fectants, whose lyric curves were similar. 
In the assay system used in Fig. 1 b, the C source was NHS, 
absorbed with mouse spleen cells and diluted to a final con- 
centration of 1:9. The source of Ab was heat-inactivated NHS, 
diluted as indicated. The classical pathway was predominantly 
responsible for lyric activity since there was no lysis in C2- 
defident human serum or in EGTA-treated NHS. EDTA treat- 
ment or 56~  heat inactivation of NHS also abolished lysis 
(not shown). 
Under these conditions, the MCP-expressing transfectant 
(MCP 3-3T3) was protected from lysis (Fig.  1 b).  60% of 
the mouse ceils transfected with the MCP construct in re- 
verse orientation were lysed while the lysis of the MCP 3-3T3 
was not above background. 
This protective effect was observed over a 16-fold range 
of Ab concentration. The mAb GB24, which blocks the 
binding of MCP to C3b (6), abrogated the protective effect. 
Relationship of MCP Expression to (23 Deposition.  Having 
established that human MCP can protect mouse cells from 
lysis by human C, the mechanism of this effect was explored. 
In these experiments, C6D human serum served both as the 
C  and Ab source. The quantity of C3 fragment deposition 
by FACS  |  analysis was inversely related to MCP expression 
(Fig. 2). Compared with the nonexpressing control (R-3T3), 
the MCP 1 transfectant (2.5  x  104 MCP/ceU) inhibited C3 
deposition by 29%, MCP 2 (1.8  x  105/ceU) by 62%, and 
MCP 3 (106/ce11) by 82%. Thus, MCP protected cells from 
C3 deposition in a dose-dependent fashion, consistent with, 
and the likely mechanism for, MCP's ability to inhibit lysis. 
Mechanism of Cytoprotection by MCP,  This set of experi- 
ments, similar in design to those decribed in Fig. 1 a, was per- 
formed to address the question of the intrinsic versus extrinsic 
inhibitory profile of MCP. The labeled and unlabeled cells 
were mixed before the addition of the serum source of C 
and Ab. 
The addition of SlCr-labded non-MCP-expressing 3T3 
cells with the unlabeled high MCP-expressing transfectant 
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Figure 1.  Protection of NIH/3T3 cells expressing human MCP from lysis by human C. The quantity of MCP expressed on each transfectant line 
is noted in Results and in Fig. 2. (a) slCr release cytotoxicity assay￿9 NHS was the source of both C and naturally occurring anti-mouse Ab. K-3T3 
is cell line transfected with an MCP construct in the reverse  orientation￿9 (b) slCr release cytotoxicity assay￿9 C source was a 1:9 dilution of NHS ab- 
sorbed with mouse spleen cells. Heat-inactivated NHS was the anti-mouse Ab source￿9  The mAb GB24, which blocks the function of MCP, was used 
at a final concentration of 10 #g/ml. A figure similar to b was published in a supplement to the October 1991 issue of Clinical  and Experimental  Immunology 
(15), and represents a summary of an invited discussion given at the Complement in Disease Workshop, University of Wales, College of Medicine, 
Cardiff, September 21-23, 1991. 
MCP  3  did not result in a reduction of lysis (Fig.  3,  open 
triangles) of the labeled cells. The other combinations of la- 
beled and/or unlabeled cells establish that there was no effect 
on lysis due to mixing of the cell populations or dilution. 
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Figure 2.  FACS  ~ analysis  of C3 fragment deposition  on MCP-expressing 
transfectants. C6D NHS served  as the C and anti-mouse Ab source. Anti- 
C3c mAb was added to detect C3 fragment deposition. 
These results indicate that MCP protects cells in an intrinsic 
fashion. 
Discussion 
MCP was initially characterized as a C3b-binding protein 
of human peripheral blood cells (23). The subsequent demon- 
stration of its broad tissue distribution and cofactor activity 
for both C3b and C4b led to the hypothesis that MCP was 
primarily a regulatory protein of the C  system (1,  10). 
Over the past  2 yr, reagents  and cell lines have become 
available that have fadlitated the study of the functional aspects 
of MCP. In particular, monodonal and polyclonal Ab to MCP 
allowed quantitation by radioassay (5, 6), ELISA (20),  and 
FACS  |  (5,  13,  14). Importantly, two mAbs were produced 
that block C3b/C4b binding and cofactor activity (5, 6, 20), 
allowing an analysis of the specificity of MCP's  activity in 
cell lysates (6) and on intact cells (13-15). Likewise, the es- 
tablishment  of transient and stable transfectants expressing 
MCP was made possible by the cloning of the MCP eDNA 
(16, 17). Oglesby et al. (14), Atkinson et al. (15), and Lublin 
and Coyne (13) have shown that expression of MCP alone 
is suffident to protect transfected mammalian cells from human 
C-mediated lysis by the classical pathway.  The purpose of 
the present investigation was to analyze the mechanism by 
which MCP protects ceUs from C3 deposition and cell lysis, 
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and to determine how the level of MCP expression influences 
these parameters. 
To investigate these points,  mouse NIH/3T3  cells were 
transfected with human MCP. These transfectants, but not 
control 3T3 cells, were protected from lysis in a system in 
which naturally occurring human Ab activated the classical 
C pathway. This protective effect was abrogated by a mAb 
that blocks C3/C4 binding and cofactor activity of MCP (6, 
20). The question was then asked if MCP expression on one 
cell population could protect against C-mediated lysis of a 
cell population not expressing MCP. Therefore, the non-MCP- 
expressing and MCP-expressing transfectants were mixed and 
exposed to human serum. Mouse cells expressing as many 
as  106  copies of MCP/cell did not protect bystander cells 
from C-mediated lysis. Therefore, MCP, like DAF (9), is an 
intrinsically acting membrane regulatory protein. 
After exposure to human serum, MCP-expressing trans- 
fectants demonstrated a reduction in C3 fragment deposi- 
tion that correlated with the number of copies of MCP ex- 
pressed on the cell. However, there was not a close correlation 
between the inhibition of lysis and the decrease in C3 frag- 
ment deposition; the results illustrated in Fig.  1 a indicate 
only minor differences in lytic protection based upon MCP 
copy number. This may relate to several factors, including 
the cofactor activity of MCP for C4b and C3b cleavage, the 
enhanced ability of MCP to inactivate the C5 convertase (24), 
and a difference in the assay system used since C6D human 
serum was used for the FACS  |  assays. Further experiments 
are necessary to address the quantitative effects of MCP ex- 
pression, the relative contribution to cell protection of its 
cofactor activity for C4b vs. C3b, and its interaction with DAF. 
In vivo,  C3b deposition on self-tissue  to the extent ob- 
served in these experiments would not be expected. Thus, 
at the usual levels of expression, MCP should be able to pro- 
tect host cells from its own C system. Previous studies have 
shown,  for  example,  that  peripheral  blood  cells  possess 
ml0,000 MCP/cell (6).  In contrast, hemopoietic and carci- 
noma cell lines can range from 2  x  104 to 106, respectively 
(6).  The latter data suggest that high MCP expression on 
tumor cells could account for some of their resistance to de- 
struction by antitumor Ab and C. In addition, in certain au- 
toimmune disorders, Ab to cellular membrane constituents 
are produced. In these situations MCP would also be protec- 
tive but, as in the model system used here, this could poten- 
tially be overcome with larger quantities of C-fixing Ab. 
The results described in this report may have an additional 
and important ramification for transplantation immunology. 
Since human MCP and DAF protect foreign cells from human 
C, these two proteins are of special interest. Xenografts fail 
because of hyperacute rejection mediated by the recipient's 
C system and, in the case of discordant xenografts, the pres- 
ence of anti-donor species Ab. In various animal models, ei- 
ther or both C pathways may be involved (reviewed in refer- 
ence  25).  The  NIH/3T3  cells  expressing  MCP  were  of 
particular interest because each NHS tested contained C and 
naturally occurring anti-mouse Ab. Exposure of the 3T3 cells 
to NHS may be similar to what occurs during transplanta- 
tion of a discordant xenograft. The expression of human MCP 
or DAF on a transplanted mammalian organ may protect the 
xenograft from attack by the human C system and thus pro- 
long survival. 
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